DEF 14A: Entero Therapeutics Seeks Shareholder Approval for Reverse Stock Split to Maintain Nasdaq Listing Amidst Financial Challenges and Board Changes

Entero Therapeutics, Inc. is seeking shareholder approval for a reverse stock split to address Nasdaq's minimum bid price requirement, alongside proposals for director elections, executive compensation, and auditor ratification at its upcoming virtual Annual Meeting on June 30, 2025.

Summary

• Entero Therapeutics, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 30, 2025, at 12:00 P.M. Eastern Time.
• Key proposals for shareholder vote include the election of five director nominees, adoption of a reverse stock split (ranging from 1:2 to 1:20), an advisory vote on executive compensation, ratification of Machias Gini & O'Connell LLP as the independent auditor for fiscal year 2025, and approval for meeting adjournment if necessary.
• The company received a Nasdaq delisting notice on September 6, 2024, for failing to maintain a minimum bid price of $1.00 per share, and was granted an extension until September 1, 2025, to regain compliance.
• The proposed reverse stock split is primarily intended to increase the per-share price of the Common Stock to meet Nasdaq's listing requirements and avoid delisting.
• Entero Therapeutics reported significant net losses: $18,059,336 for the year ended December 31, 2024, $15,794,983 for 2023, and $14,629,642 for 2022.
• Total Shareholder Return (TSR) has been negative, with an initial $100 investment declining to $(0.10) in 2024, $(28.20) in 2023, and $(48.49) in 2022.
• The company's former auditor, Forvis Mazars, LLP, resigned on August 9, 2024, citing a belief that the company could no longer generate reliable financial information, a point the company disagreed with.
• Entero Therapeutics entered into a Revolving Loan Agreement for $2,000,000 with 1396974 BC Ltd. (BC Lender) on January 27, 2025, at an 18% annual interest rate, with $700,000 disbursed as of June 4, 2025.
• The Revolving Loan Agreement included a condition for the resignation of three existing directors and the appointment of three designees from the BC Lender, leading to board changes in February 2025.
• The company announced a Rescission Agreement in March 2025 to unwind its March 13, 2024, merger with ImmunogenX, Inc. (IMGX), which will result in the cancellation of shares issued in the merger and the conveyance of IMGX LLC membership interests back to former IMGX shareholders.
• A settlement agreement was reached on May 8, 2025, related to IMGX's obligations, where Dr. Syage and a trust guaranteed and paid $5,500,000 of approximately $7.9 million owed by IMGX to a lender, and IMGX LLC agreed to pay $62,000 in attorney fees.

Sentiment

Score: 3

Explanation: The company faces severe financial distress, evidenced by persistent net losses, negative shareholder returns, and the imminent threat of Nasdaq delisting. The resignation of the former auditor due to concerns about financial reliability is a significant red flag. While management is attempting to address these issues through a reverse stock split and new financing, the high cost of new debt and the history of operational challenges indicate a highly precarious situation.

Positives

• The Board of Directors unanimously recommends voting FOR all proposed measures, indicating internal alignment on the path forward.
• The company has secured a $2,000,000 Revolving Loan Agreement, providing capital for general corporate purposes, including financing a potential public offering.
• The appointment of Machias Gini & O'Connell LLP as the new independent registered public accounting firm aims to provide stability and continuity in auditing as the company advances its business plan.
• The company has appointed an experienced Interim Chief Financial Officer, Anna Skowron, with over 14 years of accounting experience.

Negatives

• The company is currently non-compliant with Nasdaq's minimum bid price requirement, facing potential delisting if compliance is not regained by September 1, 2025.
• Entero Therapeutics has reported consistent and significant net losses for the past three fiscal years, indicating ongoing operational challenges and lack of profitability.
• The company's Total Shareholder Return has been substantially negative, reflecting a significant decline in shareholder value over the last three years.
• The former independent auditor, Forvis Mazars, LLP, resigned due to concerns about the company's ability to generate reliable financial information, raising questions about financial transparency and controls.
• The company failed to hold its annual meeting in 2024 due to insufficient funding and the need for business restructuring, highlighting severe financial constraints.
• The Revolving Loan Agreement carries a high annual interest rate of 18%, which will increase the company's financial burden.
• The company did not file a Qualified Public Equity Offering (QPEO S-1) within 45 days as stipulated by the Revolving Loan Agreement, which could trigger the resignation of BC Lender appointees from the Board.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price requirement could lead to delisting, resulting in reduced liquidity, decreased investor interest, and difficulty in raising capital.
• A reverse stock split may not guarantee a sustained increase in stock price, and the price could decline further, potentially leading to a greater percentage decline than without the split.
• Implementing a reverse stock split could decrease the liquidity of the company's common stock due to a reduced number of outstanding shares.
• Under amended Nasdaq rules, if the company effects a reverse stock split and subsequently fails to meet the minimum bid price requirement, it may not be eligible for any further compliance period, leading directly to delisting proceedings.
• The Revolving Loan Agreement includes a provision for the resignation of BC Lender appointees from the Board if a Qualified Public Equity Offering is not consummated within specified timelines, potentially impacting board stability.
• Directors and executive officers may have financial and personal interests in the proposals, which could create perceived conflicts of interest with the best interests of the company and its stockholders.

Future Outlook

Entero Therapeutics aims to maintain its Nasdaq listing by implementing a reverse stock split, with the Board determining the exact ratio between 1:2 and 1:20 within one year of the Annual Meeting. The company also intends to pursue a Qualified Public Equity Offering of at least $5,000,000 as soon as practicable to support its business plan.

Management Comments

• "On behalf of the Board of Directors and management of Entero Therapeutics, Inc. (we, us, our, Entero or the Company), a Delaware corporation, you are invited to attend our 2025 Annual Meeting of Stockholders..."
• "Our Board of Directors has approved the proposals set forth in the proxy statement and recommends that you vote in favor of each such proposal."
• "The Entero Board unanimously recommends that Entero stockholders vote FOR each of the foregoing proposals."
• "Our Board has determined that it is advisable and in the best interests of the Company and its stockholders, for us to amend our Charter to authorize our Board to effect a reverse stock split..."
• "The Board believes that the Company's compensation policies and practices are effective in achieving our goals of motivating and retaining executives by (i) rewarding excellence in leadership and sustained financial performance, and (ii) aligning our executives interests with those of our stockholders to create long-term value."
• "Our Audit Committee and Board believe that stability and continuity in the Company's auditor is important as we advance our business plan."
• "The Company disagreed with Forvis Mazars' belief (the Disagreement). Notwithstanding Forvis Mazars' resignation, the Company believed it had sufficient management and governance in place, including a full-time Chief Financial Officer and corporate controller, and an Audit Committee of the Company's Board that fully satisfied the corporate governance requirements of the Nasdaq Stock Market LLC and Securities Exchange Act Rule 10A-3."

Industry Context

Entero Therapeutics operates as a clinical-stage biopharmaceutical company focused on GI diseases, characterized by significant R&D expenditures and a lack of product revenue. The company's challenges, such as persistent net losses and the risk of Nasdaq delisting, are common for small-cap biotech firms that require substantial capital to advance drug development and often trade below major exchange listing thresholds.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• IMGX LLC, the Lender, Dr. Syage, and The Jack A. Syage and Elizabeth T. Syage Revocable Trust entered into a settlement agreement effective April 9, 2025. Under this agreement, the Guarantors (Dr. Syage and the Trust) agreed to pay $5,500,000 to the Lender to cover obligations amounting to approximately $7.9 million owed by IMGX. IMGX LLC also agreed to pay the Lender's attorneys' fees and costs of approximately $62,000. The Lender released its security interest in IMGX LLC, and a Stipulation of Dismissal with Prejudice was filed and granted on May 15, 2025, before the District Court, Boulder County, State of Colorado.

Related Party Transactions

• **ImmunogenX Merger**: On March 13, 2024, Entero merged with ImmunogenX (IMGX). Dr. Syage, a director, received 15,400 shares of Common Stock and 4,920.037 shares of Series G Preferred Stock as a result of this merger.
• **Syage Note**: On March 13, 2024, IMGX entered into a secured promissory note for $500,000 in favor of Jack Syage (a director), secured by IMGX patents and trademarks. This note was subsequently rescinded as part of the Rescission Agreement.
• **Revolving Loan Agreement**: Effective January 31, 2025, with 1396974 BC Ltd. (BC Lender). A condition of this agreement was the resignation of three existing directors and the appointment of three designees by the BC Lender (Mr. Uppal, Alson Niu, and Mr. Paolone). Alson Niu is the director and control person of the BC Lender.
• **Rescission Agreement with IMGX and IMGX Shareholders**: In March 2025, the company entered into an agreement to rescind the ImmunogenX merger. As part of this, shares issued to former IMGX shareholders, including Dr. Syage's 15,400 Common Stock and 4,920.037 Series G Preferred Stock, will be cancelled. Dr. Syage will receive 41.78% of the membership interests of IMGX LLC.
• **Settlement Agreement and Related Transactions**: On May 8, 2025, IMGX LLC entered a settlement agreement with the Lender, Dr. Syage, and The Jack A. Syage and Elizabeth T. Syage Revocable Trust. Dr. Syage and the Trust guaranteed and paid $5,500,000 of IMGX's obligations. Amended and restated loan documents provide a $2,436,338.30 revolving loan to IMGX LLC, which is unconditionally guaranteed by Dr. Syage and the Trust.

Stakeholder Impact

• **Shareholders**: Face potential dilution from future capital raises and the direct impact of a reverse stock split on their share count. The negative Total Shareholder Return indicates significant value erosion. Their vote is critical for the company's continued Nasdaq listing.
• **Employees/Executives**: Subject to changes in compensation policies and potential impacts from corporate restructuring and financial performance. Management changes have occurred, including new CEO and CFO appointments.
• **Creditors**: The company has taken on new debt with a high interest rate, and previous obligations related to the ImmunogenX merger have been restructured and settled, impacting the company's debt profile and ability to repay.
• **Customers/Suppliers**: While not directly mentioned, the company's financial instability and focus on maintaining listing could indirectly affect its operational stability and ability to engage with customers and suppliers in the long term.
• **Regulatory Bodies (Nasdaq, SEC)**: The company is actively engaged with Nasdaq to regain listing compliance, and its filings are subject to SEC scrutiny, indicating ongoing regulatory oversight.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders on June 30, 2025, to vote on the proposed resolutions.
• If approved by stockholders, the Board will determine the specific ratio for the reverse stock split (between 1:2 and 1:20) and implement it prior to the one-year anniversary of the Annual Meeting.
• The company is expected to continue efforts to consummate a Qualified Public Equity Offering of at least $5,000,000.
• The Audit Committee will conduct an annual review of the Non-Executive Director Compensation Policy prior to September 1 of each year.

Key Dates

Recommendation

Keywords

Entero Therapeutics, reverse stock split, Nasdaq listing, SEC filing, proxy statement, corporate governance, executive compensation, auditor ratification, financial performance, delisting risk, biopharmaceutical, GI disease, capital raise, shareholder meeting